Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AMSNASDAQ:BDSXNASDAQ:OPGNNASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.37-2.1%$2.60$2.32▼$4.60$15.22M0.6644,045 shs3,293 shsBDSXBiodesix$0.29-4.4%$0.42$0.17▼$2.04$42.02M0.992.43 million shs740,169 shsOPGNOpGen$4.94-0.4%$4.64$0.53▼$5.25$49.74M-1.689,587 shs1,185 shsSERASera Prognostics$1.71-3.9%$2.47$1.37▼$9.13$64.42M0.71152,866 shs392,256 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services0.00%+0.42%-11.57%-15.66%-11.57%BDSXBiodesix0.00%-5.35%+30.32%-60.30%-81.38%OPGNOpGen0.00%+5.11%+5.11%+280.00%+93.73%SERASera Prognostics0.00%+10.32%-28.15%-57.99%-79.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMSAmerican Shared Hospital Services2.3651 of 5 stars0.05.00.00.02.21.71.9BDSXBiodesix3.3159 of 5 stars4.42.00.00.02.42.50.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.5049 of 5 stars0.02.00.00.01.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMSAmerican Shared Hospital Services 0.00N/AN/AN/ABDSXBiodesix 2.80Moderate Buy$1.75510.39% UpsideOPGNOpGen 0.00N/AN/AN/ASERASera Prognostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AMS, SERA, BDSX, and OPGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.005/14/2025BDSXBiodesixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $2.005/14/2025BDSXBiodesixCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.505/14/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $1.505/14/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform4/29/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.50(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMSAmerican Shared Hospital Services$21.33M0.71$0.80 per share2.97$4.17 per share0.57BDSXBiodesix$74.46M0.56N/AN/A$0.05 per share5.73OPGNOpGen$2.67M18.61N/AN/A($11.55) per share-0.43SERASera Prognostics$115K560.18N/AN/A$2.21 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMSAmerican Shared Hospital Services$610K$0.603.957.90N/A15.74%4.01%2.11%8/12/2025 (Estimated)BDSXBiodesix-$52.15M-$0.29N/AN/AN/A-66.84%-275.79%-43.05%8/6/2025 (Estimated)OPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)SERASera Prognostics-$36.24M-$0.94N/AN/AN/AN/A-51.73%-36.94%8/6/2025 (Estimated)Latest AMS, SERA, BDSX, and OPGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/13/2025Q1 2025BDSXBiodesix-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/ABDSXBiodesixN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMSAmerican Shared Hospital Services0.341.461.46BDSXBiodesix1.303.403.40OPGNOpGenN/A5.455.45SERASera PrognosticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMSAmerican Shared Hospital Services23.16%BDSXBiodesix20.96%OPGNOpGen2.68%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipAMSAmerican Shared Hospital Services23.00%BDSXBiodesix30.10%OPGNOpGen43.80%SERASera Prognostics13.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMSAmerican Shared Hospital Services106.42 million4.94 millionNot OptionableBDSXBiodesix220146.56 million44.80 millionOptionableOPGNOpGen10010.07 million4.70 millionNot OptionableSERASera Prognostics12037.67 million28.44 millionOptionableAMS, SERA, BDSX, and OPGN HeadlinesRecent News About These CompaniesSera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $32,950.06 in StockJune 12 at 9:37 AM | insidertrades.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells 23,042 Shares of StockJune 11, 2025 | marketbeat.comWe Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth CarefullyJune 10, 2025 | finance.yahoo.comSera Prognostics (NASDAQ:SERA) Cut to Sell at Wall Street ZenJune 9, 2025 | americanbankingnews.comsera prognostics announces board elections and auditor ratificationJune 7, 2025 | investing.comSera Prognostics (NASDAQ:SERA) Rating Lowered to "Sell" at Wall Street ZenJune 7, 2025 | marketbeat.comAfter Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)May 29, 2025 | zacks.comSERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESMay 29, 2025 | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial ResultsMay 26, 2025 | finanznachrichten.deSERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCEMay 14, 2025 | prnewswire.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comDown -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a TurnaroundMay 13, 2025 | zacks.comSera Prognostics Inc (SERA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in StockMay 10, 2025 | insidertrades.comSera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial OfficerMay 9, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics reports Q1 2025 earnings beatMay 9, 2025 | investing.comSera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization ProgressesMay 9, 2025 | 360dx.comWhat I Wish I Knew: The Truth About Preterm Birth for Black WomenMay 9, 2025 | blackdoctor.orgSERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICERMay 8, 2025 | prnewswire.comSera Prognostics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comSera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueMicrosoft Could Rally as EU Antitrust Case Nears ResolutionBy Chris Markoch | May 21, 2025View Microsoft Could Rally as EU Antitrust Case Nears ResolutionWilliams-Sonoma: A Fundamentally Good Buy On Sale NowBy Thomas Hughes | May 23, 2025View Williams-Sonoma: A Fundamentally Good Buy On Sale NowIgnore the Noise—Samsara Stock Is Still a Strong BuyBy Sam Quirke | June 12, 2025View Ignore the Noise—Samsara Stock Is Still a Strong BuyAMS, SERA, BDSX, and OPGN Company DescriptionsAmerican Shared Hospital Services NYSEAMERICAN:AMS$2.37 -0.05 (-2.07%) Closing price 06/13/2025 04:10 PM EasternExtended Trading$2.36 -0.01 (-0.42%) As of 06/13/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.Biodesix NASDAQ:BDSX$0.29 -0.01 (-4.40%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+1.15%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.OpGen NASDAQ:OPGN$4.94 -0.02 (-0.40%) As of 06/13/2025 10:53 AM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Sera Prognostics NASDAQ:SERA$1.71 -0.07 (-3.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.71 0.00 (0.00%) As of 06/13/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
